Back to News
Market Impact: 0.25
Spyre's SPY072 Shows Mixed Efficacy In Phase 2 RA Study, Fails Internal Bar For Monotherapy
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Spyre Therapeutics reported topline Phase 2 SKYWAY basket-trial results for its rheumatoid arthritis (RA) sub-study of SPY072, with both doses showing benefits on one or more efficacy endpoints. The company indicated the magnitude of effect (text truncated), implying measurable clinical activity. Overall, the update is modestly positive for the SPY072 RA development program and could modestly support sentiment around SYRE.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SYRE0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off